Compare FEAM & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | CCEL |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.1M | 32.7M |
| IPO Year | N/A | 1997 |
| Metric | FEAM | CCEL |
|---|---|---|
| Price | $3.54 | $3.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.13 | N/A |
| AVG Volume (30 Days) | ★ 84.1K | 4.1K |
| Earning Date | 11-13-2025 | 10-15-2025 |
| Dividend Yield | N/A | ★ 10.81% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $500.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.82 | $3.57 |
| 52 Week High | $24.84 | $8.79 |
| Indicator | FEAM | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 49.01 |
| Support Level | $3.68 | $3.58 |
| Resistance Level | $4.21 | $4.38 |
| Average True Range (ATR) | 0.26 | 0.31 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 21.84 | 51.67 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.